Alpha Tau Medical (DRTS) Non-Current Debt (2023 - 2026)
Alpha Tau Medical (DRTS) posted Non-Current Debt of $6.4 million for Q1 2026, up 0.8% sequentially from $6.4 million in Q4 2025, and up 17.01% YoY from $5.5 million in Q1 2025.
Analysis
Alpha Tau Medical (DRTS) Non-Current Debt (2023 - 2026) Analysis & Trends
Alpha Tau Medical has reported Non-Current Debt for 4 years, with the latest figure at $6.4 million in Q1 2026.
- Quarterly Non-Current Debt rose 17.01% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 17.01% YoY) and the FY2025 annual result came in at $6.4 million, up 14.22% from the prior year.
- Non-Current Debt grew to $6.4 million in Q1 2026 per DRTS's latest filing, from $6.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $6.4 million in Q1 2026 and troughed at $5.4 million in Q2 2024.
- A 4-year average of $5.8 million and a median of $5.6 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt slipped 0.98% in 2025, then gained 17.01% in 2026.
- Over 4 years, Non-Current Debt stood at $5.6 million in 2023, then decreased by 0.87% to $5.6 million in 2024, then climbed by 14.22% to $6.4 million in 2025, then advanced by 0.8% to $6.4 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $6.4 million, $6.4 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Alpha Tau Medical | 1.21 Bn | 1.11 Bn | - | 6.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.80 Mn |
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | 6.35 Mn |
| Sep 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 6.03 Mn |
| Mar 31, 2025 | 5.47 Mn |
| Dec 31, 2024 | 5.56 Mn |
| Sep 30, 2024 | 5.48 Mn |
| Jun 30, 2024 | 5.41 Mn |
| Mar 31, 2024 | 5.53 Mn |
| Dec 31, 2023 | 5.61 Mn |